Loading stock data…
IMMX
$9.30+0.37 (+4.14%)
Market ClosedLast close May 1
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Immix Biopharma, Inc. in the Healthcare sector is trading at $9.30. The stock is currently 20% below its 52-week high of $11.61, remaining 78.2% above its 200-day moving average. Technical signals show neutral RSI of 45 and bearish MACD signal, explaining why IMMX maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$9.30
Potential Upside
5%
Whystock Fair Value$9.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead prod...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$539.13M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.21
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-31.39%
Volume
Today's trading volume
803,829
Recent News
Breakeven On The Horizon For Immix Biopharma, Inc. (NASDAQ:IMMX)
We feel now is a pretty good time to analyse Immix Biopharma, Inc.'s ( NASDAQ:IMMX ) business as it appears the company...
We Think Immix Biopharma (NASDAQ:IMMX) Needs To Drive Business Growth Carefully
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Immix...
Immix Biopharma, Inc. (NASDAQ:IMMX) surges 10%; individual investors who own 56% shares profited along with insiders
Key Insights Immix Biopharma's significant individual investors ownership suggests that the key decisions are...
Discover Immix Biopharma And 2 Other Promising Penny Stocks
As the U.S. stock market experiences a rise, buoyed by recent labor market data and anticipation of the August jobs report, investors are keenly observing potential shifts in monetary policy. Amidst this backdrop, penny stocks continue to intrigue those looking for opportunities beyond the mainstream indices. Although often associated with smaller or newer companies, these stocks can offer significant growth potential when supported by strong financials and robust fundamentals. In this...
Immix Biopharma Loses US$9.2m Market Value But Insiders See Windfall Of US$19k
Insiders who bought Immix Biopharma, Inc. ( NASDAQ:IMMX ) in the last 12 months may probably not pay attention to the...